<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Dual-pathway susceptibility: exposure-mediated vs repair/senescence-mediated carcinogenesis (DPS-ERS) - Theorizer</title>
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/5.15.1/css/all.min.css">
    <link rel="stylesheet" href="../style.css">
</head>
<body>
    <div class="header">
        <a href="../index.html"><i class="fas fa-flask"></i> Theorizer</a>
    </div>

    <div class="content">
        <h1>Theory Details for theory-16</h1>

        <div class="section">
            <h2>Theory (General Information)</h2>
            <div class="info-section">
                <p><strong>ID:</strong> theory-16</p>
                <p><strong>Name:</strong> Dual-pathway susceptibility: exposure-mediated vs repair/senescence-mediated carcinogenesis (DPS-ERS)</p>
                <p><strong>Type:</strong> general</p>
                <p><strong>Theory Query:</strong> Build a theory of why only some cigarette smokers develop lung cancer while others do not, despite smoking being a strong risk factor, based on the following results.</p>
                <p><strong>Description:</strong> Smokers diverge in lung cancer risk because at least two mechanistically distinct pathways lead to disease: (A) an exposure-mediated pathway where genes and behaviors increase cigarette consumption and carcinogen dose (e.g., 15q25 nicotinic receptor locus), and (B) an exposure-independent (or weakly exposure-dependent) vulnerability pathway where inherited differences in genome maintenance, apoptosis, and replicative immortality (e.g., 5p15.33 TERT/CLPTM1L) increase the probability that a given amount of damage yields malignant transformation. These pathways can coexist, but they predict different patterns: pathway A shows strong correlation with smoking intensity, while pathway B shows relatively stable effects across never/ex/current smokers and after smoking adjustment.</p>
                <p><strong>Knowledge Cutoff Year:</strong> 2029</p>
                <p><strong>Knowledge Cutoff Month:</strong> 12</p>
                <p><strong>Base Model:</strong> openai/gpt-5.2-2025-12-11</p>
            </div>
        </div>
        </div>

        <div class="section">
            <h2>Theory (Statement/Laws)</h2>

            <h3>Theory Statements/Laws</h3>
            <hr/>
            <h3>Statement 0: Behaviorally mediated genetic risk (dose-amplification locus)</h3>
            <p><strong>Statement:</strong> Common germline variants that increase nicotine dependence amplify lung cancer risk primarily by increasing effective tobacco exposure (dose), producing an allele-dose relationship in lung cancer risk that is partly mediated by smoking behavior.</p>
            <p><strong>Domain/Scope:</strong> Applies to populations where variants in the CHRNA5–CHRNA3–CHRNB4 region (15q25) are present and smoking behavior varies; relevant mainly to ever-smokers.</p>
            <h4>Special Cases</h4>
            <ol>
                <li>Some 15q25 effects may be direct (receptor biology) rather than purely mediated by behavior; mediation fraction may differ by cohort and measurement quality.</li>
                <li>If smoking intensity is poorly measured, behavior-mediated effects may appear 'direct'.</li>
            </ol>
            <h4>Supporting Evidence for this Law</h4>
<ol>
    <li>Three independent genetic studies identified a 15q25 marker associated with ~30% increased lung cancer risk for one copy and ~70–80% for two copies, with the region containing nicotinic receptor genes hypothesized to increase nicotine addiction and thus exposure. <a href="../results/extraction-result-89.html#e89.1" class="evidence-link">[e89.1]</a> <a href="../results/extraction-result-88.html#e88.3" class="evidence-link">[e88.3]</a> </li>
    <li>Reviews explicitly discuss the mechanistic pathway gene → nicotine dependence → higher smoking dose → higher lung cancer risk. <a href="../results/extraction-result-89.html#e89.1" class="evidence-link">[e89.1]</a> <a href="../results/extraction-result-88.html#e88.3" class="evidence-link">[e88.3]</a> <a href="../results/extraction-result-88.html#e88.10" class="evidence-link">[e88.10]</a> </li>
</ol>            <h4>Self-Evaluation of Law Novelty (produced by the generation model)</h4>
            <p><strong>Likely Classification:</strong> closely-related-to-existing</p>
        <p><strong>Explanation:</strong> Integrative re-interpretation rather than a new association; novelty is the explicit dual-pathway discrimination and predictions.</p>            <p><strong>What Already Exists:</strong> 15q25 is an established lung cancer/nicotine dependence locus; behavior-mediated risk is widely discussed.</p>            <p><strong>What is Novel:</strong> Places 15q25 into a two-pathway framework that predicts separable mediation signatures compared with exposure-independent loci (e.g., 5p15.33).</p>
        <p><strong>References:</strong> <ul>
    <li>Amos et al. (2008) and related 15q25 GWAS [nicotinic receptor locus; addiction mediation]</li>
</ul>
            <h4>External Evaluations of this Law</h4>
            <p><strong>Predictive Accuracy Evaluation:</strong> <span class="empty-note">Not available.</span></p>
            <p><strong>Novelty Evaluation:</strong> <span class="empty-note">Not available (available only for a randomly selected subset of 100 laws, due to cost).</span></p>
            <hr/>
            <h3>Statement 1: Exposure-independent vulnerability (telomere/apoptosis locus)</h3>
            <p><strong>Statement:</strong> Germline variation in loci affecting telomere maintenance and genotoxic-stress apoptosis modifies lung cancer risk largely independently of measured smoking dose, contributing to why some smokers develop cancer at modest exposure while others with high exposure do not.</p>
            <p><strong>Domain/Scope:</strong> Applies to populations similar to the European-ancestry GWAS/replication cohorts and to loci at 5p15.33 (TERT/CLPTM1L) where associations persist after smoking adjustment and across smoking strata.</p>
            <h4>Special Cases</h4>
            <ol>
                <li>Self-reported pack-years may not capture true internal dose; 'independence' is with respect to measured exposure, not necessarily true biologic dose.</li>
                <li>Effects may vary by ancestry due to LD differences and causal variant frequency.</li>
            </ol>
            <h4>Supporting Evidence for this Law</h4>
<ol>
    <li>GWAS identified 5p15.33 variants rs402710 and rs2736100 with smoking-adjusted per-allele OR ~1.19 and ~1.11; association observed in never-, ex- and current smokers; rs402710 not associated with cigarettes/day among controls (p=0.74), indicating effect not mediated by measured smoking intensity. <a href="../results/extraction-result-105.html#e105.0" class="evidence-link">[e105.0]</a> </li>
    <li>Authors propose mechanisms: TERT variation affecting telomere maintenance and CLPTM1L affecting apoptosis under genotoxic stress, consistent with exposure-independent susceptibility. <a href="../results/extraction-result-105.html#e105.0" class="evidence-link">[e105.0]</a> </li>
</ol>            <h4>Self-Evaluation of Law Novelty (produced by the generation model)</h4>
            <p><strong>Likely Classification:</strong> <span style="color: orange; font-weight: bold;">somewhat-related-to-existing</span></p>
        <p><strong>Explanation:</strong> Uses known loci but offers a clearer mechanistic taxonomy useful for prediction and for explaining smoker heterogeneity.</p>            <p><strong>What Already Exists:</strong> 5p15.33 is a known susceptibility locus and is commonly interpreted via telomere biology and apoptosis.</p>            <p><strong>What is Novel:</strong> Explicitly formalizes it as a separate pathway from exposure-mediated genetic effects and predicts contrasting mediation/interaction patterns with internal-dose biomarkers.</p>
        <p><strong>References:</strong> <ul>
    <li>McKay et al. (2008) Lung cancer susceptibility locus at 5p15.33 [TERT/CLPTM1L; smoking-adjusted association]</li>
</ul>
            <h4>External Evaluations of this Law</h4>
            <p><strong>Predictive Accuracy Evaluation:</strong> <span class="empty-note">Not available.</span></p>
            <p><strong>Novelty Evaluation:</strong> <span class="empty-note">Not available (available only for a randomly selected subset of 100 laws, due to cost).</span></p>
            <hr/>
        </div>
        <div class="section">
            <h2>Theory (Additional Details)</h2>
                        <h3>New Predictions (Likely outcome)</h3>
            <ol>
                <li>In cohorts with biomarker-verified tobacco exposure, 15q25 effects will substantially attenuate after adjusting for internal-dose biomarkers, whereas 5p15.33 effects will remain similar.</li>
                <li>Smokers with high-risk 5p15.33 genotypes will develop lung cancer at lower pack-years on average than non-carriers, but without higher cigarettes/day among controls.</li>
            </ol>
            <h3>New Predictions (Unknown outcome/high-entropy)</h3>
            <ol>
                <li>Combining a dependence/behavior PRS (including 15q25) with a genome-maintenance PRS (including 5p15.33) will identify a small subgroup of smokers whose lifetime lung cancer risk approaches the high end (~30%) even at moderate pack-years.</li>
                <li>5p15.33 risk alleles will correlate with measurable pre-cancer intermediate phenotypes (e.g., telomere length dynamics in airway epithelial cells or altered apoptosis thresholds) that predict incidence.</li>
            </ol>
            <h3>Negative Experiments</h3>
            <ol>
                <li>If 15q25 variants predict lung cancer equally strongly in never-smokers or show no relationship to any smoking behavior/intensity measures in well-measured cohorts, the exposure-mediated pathway claim is weakened.</li>
                <li>If 5p15.33 associations disappear after precise internal-dose biomarker adjustment, its classification as exposure-independent vulnerability would be undermined.</li>
            </ol>
            <h3>Unaccounted for Evidence</h3>
<ol>
    <li>Very strong effects of COPD/fibrosis and inflammation markers suggest an additional tissue-context 'gate' not fully captured by the two-pathway genetic framing. <a href="../results/extraction-result-116.html#e116.5" class="evidence-link">[e116.5]</a> <a href="../results/extraction-result-85.html#e85.2" class="evidence-link">[e85.2]</a> <a href="../results/extraction-result-80.html#e80.0" class="evidence-link">[e80.0]</a> </li>
    <li>Somatic driver subtype heterogeneity (EGFR/ALK vs KRAS/TP53 patterns) is tumor-evolution level and not fully predicted by germline pathways alone. <a href="../results/extraction-result-86.html#e86.1" class="evidence-link">[e86.1]</a> <a href="../results/extraction-result-87.html#e87.1" class="evidence-link">[e87.1]</a> <a href="../results/extraction-result-89.html#e89.7" class="evidence-link">[e89.7]</a> <a href="../results/extraction-result-104.html#e104.0" class="evidence-link">[e104.0]</a> </li>
</ol>        </div>        <div style="height: 30px;"></div>
    </div>
</body>
</html>